Case Report: Successful Reversal of Crizotinib-Induced Acute Liver Failure in Metastatic Lung Adenocarcinoma Using a Multi-Agent Therapeutic Approach

Introduction Metastatic lung adenocarcinoma patients treated with crizotinib may rarely develop severe adverse effects, including acute liver failure. Early recognition and management of drug-induced liver injury are crucial for patient outcomes. Case Presentation We report a 52-year-old female diagnosed with metastatic lung adenocarcinoma who developed acute liver failure during crizotinib therapy. After starting the second cycle, she presented with weakness, anorexia, and jaundice. Comprehensive clinical evaluation and laboratory tests confirmed drug-induced liver injury. The patient received supportive treatment, including intravenous N-acetylcysteine, dexamethasone, vitamin K, ursodeoxycholic acid, and rifampicin. Liver function tests and bilirubin levels were closely monitored. Conclusions The patient’s liver enzymes and bilirubin levels gradually normalized with appropriate supportive care. This case highlights the importance of vigilant hepatic monitoring during crizotinib treatment to promptly identify and manage potential hepatotoxicity.